PFE News 30.86 04/21/2014 21:44:10 Pfizer Inc (PFE)
Post# of 273322
Posted On: 04/21/2014 10:44:12 PM
Pfizer Inc (PFE) 30.86 $PFE
Netflix Jumps on Earnings; Ford Taps Next CEO
Jeremy Bowman, The Motley Fool - Motley Fool - 43 mins ago
Stocks didn't miss a beat coming back from the long weekend, as all three indexes added to last week's gains today. As earnings season heats up this week, investors seem to be encouraged by mostly upside reports from the financial sector last week...
Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 39 mins ago
The Dow Jones Industrials rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer and Merck , which gained 2%...
Valeant to bid for Botox maker Allergan
By KEN SWEET and MATTHEW PERRONE - AP - 2 hrs 35 mins ago
NEW YORK (AP) — Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.
Pfizer may make cancer play
at Investor's Business Daily - Mon Apr 21, 5:42PM CDT
AstraZeneca's (AZN) pipeline of cancer drugs may draw Pfizer (PFE) back for another look after its earlier $101 bil proposed purchase was rejected, reports said. AstraZeneca has a line of experimental drugs called immunotherapies that show promise of...
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
The iShares Nasdaq Biotechnology Index finally put up some gains last week as some big names released great news. It looks like GlaxoSmithKline might have an oral psoriasis candidate. Hemophilia giant Baxter might be adding another therapy to...
Most active New York Stock Exchange-traded stocks
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Pfizer Set to Possibly Pullback After Yesterday's Rally of 2.02%
Comtex SmarTrend(R) - Mon Apr 21, 3:45PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.40 to a high of $30.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $30.40 on volume of 30.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Pfizer After 2.02% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:44PM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $30.40 to a high of $30.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $30.40 on volume of 30.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Supreme Court Denies Teva's Request - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:35PM CDT
The U.S. Supreme Court denied Teva's appeal of a decision from the U.S. Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 covering Teva's relapsing-remitting multiple sclerosis (RRMS) product, Copaxone 20mg/mL.
Is Pfizer Eyeing AstraZeneca? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:30PM CDT
According to a report by UK's Sunday Times, Pfizer is looking to acquire AstraZeneca for about $101 billion.
Stocks Rise In Weak Volume; Pfizer Paces Drugmakers
at Investor's Business Daily - Mon Apr 21, 3:27PM CDT
Stocks rose in slow volume Monday, with the S&P 500 rising for a fifth straight session, ahead of key earnings reports. The Nasdaq advanced 0.6%, while the S&P 500 rose 0.3% and the Dow Jones industrials edged up 0.2% each. Volume was sharply lower...
Stocks Up, But Slow Trade Points To Lack Of Big Money
at Investor's Business Daily - Mon Apr 21, 2:00PM CDT
Stocks rose in slow volume Monday afternoon, showing scant evidence that the big-money players were back from the holiday. The Nasdaq advanced 0.5%, while the S&P 500 and the Dow Jones industrial added 0.3% each. Volume was running sharply lower vs....
Kaplan Fox Announces $190 Million Settlement with Pfizer, Inc. and Warner-Lambert Co.
PR Newswire - Mon Apr 21, 1:42PM CDT
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $190 Million settlement, subject to court approval, with Pfizer, Inc. and Warner-Lambert Co. ("Defendants"
in In re Neurontin Antitrust Litigation, No. 02-1390, pending in the District of New Jersey.
Pfizer's Missed Megadeal Sparks the Dow's Rise
Dan Carroll, The Motley Fool - Motley Fool - Mon Apr 21, 1:37PM CDT
The market opened the week on an upbeat note, with the major stock indices all modestly on the upswing. The Dow Jones Industrial Average was up more than 45 points as of 2:35 p.m. EDT. Big Pharma's Pfizer has led the Dow's gain so far today,...
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Dow Today: Pfizer (PFE) Higher
at The Street - Mon Apr 21, 1:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a 60-cent gain (+2%) bringing the stock to $30.85.
Why Pfizer (PFE) Stock Is Up Today
at The Street - Mon Apr 21, 12:45PM CDT
Pfizer (PFE) rose Monday amid reports that the U.S. pharmaceutical giant has approached British rival AstraZeneca (AZN) about a $101 billion takeover. Britain's Sunday Times cited senior investment bankers and other sources within the industry to...
Netflix Jumps on Earnings; Ford Taps Next CEO
Jeremy Bowman, The Motley Fool - Motley Fool - 43 mins ago
Stocks didn't miss a beat coming back from the long weekend, as all three indexes added to last week's gains today. As earnings season heats up this week, investors seem to be encouraged by mostly upside reports from the financial sector last week...
Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 39 mins ago
The Dow Jones Industrials rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer and Merck , which gained 2%...
Valeant to bid for Botox maker Allergan
By KEN SWEET and MATTHEW PERRONE - AP - 2 hrs 35 mins ago
NEW YORK (AP) — Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.
Pfizer may make cancer play
at Investor's Business Daily - Mon Apr 21, 5:42PM CDT
AstraZeneca's (AZN) pipeline of cancer drugs may draw Pfizer (PFE) back for another look after its earlier $101 bil proposed purchase was rejected, reports said. AstraZeneca has a line of experimental drugs called immunotherapies that show promise of...
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
The iShares Nasdaq Biotechnology Index finally put up some gains last week as some big names released great news. It looks like GlaxoSmithKline might have an oral psoriasis candidate. Hemophilia giant Baxter might be adding another therapy to...
Most active New York Stock Exchange-traded stocks
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Apr 21, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Pfizer Set to Possibly Pullback After Yesterday's Rally of 2.02%
Comtex SmarTrend(R) - Mon Apr 21, 3:45PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.40 to a high of $30.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $30.40 on volume of 30.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. SmarTrend Watching for Potential Pullback in Shares of Pfizer After 2.02% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:44PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $30.40 to a high of $30.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $30.40 on volume of 30.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Supreme Court Denies Teva's Request - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:35PM CDT
The U.S. Supreme Court denied Teva's appeal of a decision from the U.S. Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 covering Teva's relapsing-remitting multiple sclerosis (RRMS) product, Copaxone 20mg/mL.
Is Pfizer Eyeing AstraZeneca? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:30PM CDT
According to a report by UK's Sunday Times, Pfizer is looking to acquire AstraZeneca for about $101 billion.
Stocks Rise In Weak Volume; Pfizer Paces Drugmakers
at Investor's Business Daily - Mon Apr 21, 3:27PM CDT
Stocks rose in slow volume Monday, with the S&P 500 rising for a fifth straight session, ahead of key earnings reports. The Nasdaq advanced 0.6%, while the S&P 500 rose 0.3% and the Dow Jones industrials edged up 0.2% each. Volume was sharply lower...
Stocks Up, But Slow Trade Points To Lack Of Big Money
at Investor's Business Daily - Mon Apr 21, 2:00PM CDT
Stocks rose in slow volume Monday afternoon, showing scant evidence that the big-money players were back from the holiday. The Nasdaq advanced 0.5%, while the S&P 500 and the Dow Jones industrial added 0.3% each. Volume was running sharply lower vs....
Kaplan Fox Announces $190 Million Settlement with Pfizer, Inc. and Warner-Lambert Co.
PR Newswire - Mon Apr 21, 1:42PM CDT
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $190 Million settlement, subject to court approval, with Pfizer, Inc. and Warner-Lambert Co. ("Defendants"
in In re Neurontin Antitrust Litigation, No. 02-1390, pending in the District of New Jersey. Pfizer's Missed Megadeal Sparks the Dow's Rise
Dan Carroll, The Motley Fool - Motley Fool - Mon Apr 21, 1:37PM CDT
The market opened the week on an upbeat note, with the major stock indices all modestly on the upswing. The Dow Jones Industrial Average was up more than 45 points as of 2:35 p.m. EDT. Big Pharma's Pfizer has led the Dow's gain so far today,...
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Dow Today: Pfizer (PFE) Higher
at The Street - Mon Apr 21, 1:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a 60-cent gain (+2%) bringing the stock to $30.85.
Why Pfizer (PFE) Stock Is Up Today
at The Street - Mon Apr 21, 12:45PM CDT
Pfizer (PFE) rose Monday amid reports that the U.S. pharmaceutical giant has approached British rival AstraZeneca (AZN) about a $101 billion takeover. Britain's Sunday Times cited senior investment bankers and other sources within the industry to...
(0)
(0)